Solar urticaria treated with intravenous immunoglobulins

2011 ◽  
Vol 65 (2) ◽  
pp. 336-340 ◽  
Author(s):  
Henri Adamski ◽  
Christophe Bedane ◽  
Annie Bonnevalle ◽  
Pierre Thomas ◽  
Jean-Louis Peyron ◽  
...  
Keyword(s):  
Intravenous Immunoglobulins ◽  
Solar Urticaria

Solar urticaria unresponsive to intravenous immunoglobulins

2011 ◽  
Vol 27 (1) ◽  
pp. 53-54 ◽  
Author(s):  
Mar Llamas-Velasco ◽  
Diego De Argila ◽  
Cristina Eguren ◽  
Patricia García-Martin ◽  
Sara Ibañes ◽  
...  
Keyword(s):  
Intravenous Immunoglobulins ◽  
Solar Urticaria

Solar Urticaria Successfully Treated with Intravenous Immunoglobulins

Dermatology ◽  
2009 ◽  
Vol 218 (3) ◽  
pp. 252-254 ◽  
Author(s):  
Laurent Maksimovic ◽  
Guillemette Frémont ◽  
Michel Jeanmougin ◽  
Louis Dubertret ◽  
Manuelle Viguier
Keyword(s):  
Intravenous Immunoglobulins ◽  
Solar Urticaria

Severe and refractory solar urticaria treated with intravenous immunoglobulins: A phase II multicenter study

2014 ◽  
Vol 71 (5) ◽  
pp. 948-953.e1 ◽  
Author(s):  
François Aubin ◽  
Raphaël Porcher ◽  
Michel Jeanmougin ◽  
Fabienne Léonard ◽  
Christophe Bedane ◽  
...  
Keyword(s):  
Phase Ii ◽  
Multicenter Study ◽  
Intravenous Immunoglobulins ◽  
Solar Urticaria

Solar urticaria

1979 ◽  
Vol 115 (6) ◽  
pp. 759-759 ◽  
Author(s):  
E. Van Hecke
Keyword(s):  
Solar Urticaria

ITI with high-dose FIX and combined immunosuppressive therapy in a patient with severe haemophilia B and inhibitor

2009 ◽  
Vol 29 (02) ◽  
pp. 155-157 ◽  
Author(s):  
H. Hauch ◽  
J. Rischewski ◽  
U. Kordes ◽  
J. Schneppenheim ◽  
R. Schneppenheim ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Immunosuppressive Agents ◽  
Tolerance Induction ◽  
Intravenous Immunoglobulins ◽  
Factor Ix ◽  
High Dose ◽  
Allergic Reactions ◽  
Success Rates ◽  
Serious Infections ◽  
History Of

SummaryInhibitor development is a rare but serious event in hemophilia B patients. Management is hampered by the frequent occurrence of allergic reactions to factor IX, low success rates of current inhibitor elimination protocols and the risk of development of nephrotic syndrome. Single cases of immune tolerance induction (ITI) including immunosuppressive agents like mycophenolat mofetil (MMF) or rituximab have been reported. We present a case of successful inhibitor elimination with a combined immune-modulating therapy and high-dose factor IX (FIX). This boy had developed a FIX inhibitor at the age of 5 years and had a history of allergic reactions to FIX and to FEIBA→. Under on-demand treatment with recombinant activated FVII the inhibitor became undetectable but the boy suffered from multiple joint and muscle bleeds. At the age of 11.5 years ITI was attempted with a combination of rituximab, MMF, dexamethasone, intravenous immunoglobulins and high-dose FIX. The inhibitor did not reappear and FIX half-life normalized. No allergic reaction, no signs of nephrotic syndrome and no serious infections were observed.

Successful Treatment of Lupus Anticoagulant-Hypoprothrombinemia Syndrome Using Intravenous Immunoglobulins

1997 ◽  
Vol 78 (02) ◽  
pp. 969-970 ◽  
Author(s):  
Gilles Pernod ◽  
Josiane Arvieux ◽  
Patrick H Carpentier ◽  
Pascal Mossuz ◽  
Jean Luc Bosson ◽  
...  
Keyword(s):  
Successful Treatment ◽  
Lupus Anticoagulant ◽  
Intravenous Immunoglobulins
Sign in / Sign up

Export Citation Format

Share Document